This trial will test if mepolizumab is an effective and safe treatment for children and adolescents with HES who are already receiving standard care therapy.
1 Primary · 8 Secondary · Reporting Duration: Weeks 0 to 4 and Weeks 48 to 52
Experimental Treatment
25 Total Participants · 1 Treatment Group
Primary Treatment: Mepolizumab · No Placebo Group · Phase 3
Age 6 - 17 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: